A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study (called DLLEVATE) is comparing a new drug called ZL-1310 against the doctor's choice of treatment for people with small cell lung cancer (SCLC) that has come back after initial treatment. Small cell lung cancer is a fast-growing form of lung cancer that often returns after first-line therapy.
**You may be eligible if...**
- You are 18 or older and have been confirmed to have small cell lung cancer
- Your cancer has come back or worsened after receiving first-line platinum-based chemotherapy, or after second-line tarlatamab treatment
- Your cancer can be measured on a scan
- You are generally healthy enough to undergo treatment (ECOG performance status 0 or 1)
- Your life expectancy is at least 3 months
- You are willing to provide a tumor biopsy or archived tissue sample
**You may NOT be eligible if...**
- You have received more than one prior line of chemotherapy for extensive-stage SCLC
- You have previously received certain antibody-drug conjugates (ADCs) with a topoisomerase 1 inhibitor
- You have a history of certain lung inflammation (ILD/pneumonitis)
- You have another active cancer
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZL-1310
ZL-1310 as a single-agent
DRUGInvestigator's Choice of Therapy
Topotecan, Lurbinectedin, or Amrubicin
Locations(76)
Zai Lab Site 02050
La Jolla, California, United States
Zai Lab Site 02033
Sacramento, California, United States
Zai Lab Site 02037
Aurora, Colorado, United States
Zai Lab Site 02030
New Haven, Connecticut, United States
Zai Lab Site 02045
Clermont, Florida, United States
Zai Lab Site 02031
Orange City, Florida, United States
Zai Lab Site 02020
Rockledge, Florida, United States
Zai Lab Site 02026
Sarasota, Florida, United States
Zai Lab Site 02052
St. Petersburg, Florida, United States
Zai Lab Site 02047
Tampa, Florida, United States
Zai Lab Site 02051
West Palm Beach, Florida, United States
Zai Lab Site 02021
Peoria, Illinois, United States
Zai Lab Site 02049
Peoria, Illinois, United States
Zai Lab Site 02038
Iowa City, Iowa, United States
Zai Lab Site 02041
Louisville, Kentucky, United States
Zai Lab Site 02003
Bethesda, Maryland, United States
Zai Lab Site 02022
Silver Spring, Maryland, United States
Zai Lab Site 02010
Detroit, Michigan, United States
Zai Lab Site 02023
Columbia, Missouri, United States
Zai Lab Site 02009
St Louis, Missouri, United States
Zai Lab Site 02040
The Bronx, New York, United States
Zai Lab Site 02024
Cleveland, Ohio, United States
Zai Lab Site 02035
Broomall, Pennsylvania, United States
Zai Lab Site 02019
Media, Pennsylvania, United States
Zai Lab Site 02008
Pittsburgh, Pennsylvania, United States
Zai Lab Site 02029
Pittsburgh, Pennsylvania, United States
Zai Lab Site 02036
Nashville, Tennessee, United States
Zai Lab Site 02025
Austin, Texas, United States
Zai Lab Site 02046
Dallas, Texas, United States
Zai Lab Site 02025
Odessa, Texas, United States
Zai Lab Site 02006
Fairfax, Virginia, United States
Zai Lab Site 22002
Salzburg, Austria
Zai Lab Site 01002
Hefei, Anhui, China
Zai Lab Site 01014
Xiamen, Fujian, China
Zai Lab Site 01001
Guangzhou, Guangdong, China
Zai Lab Site 01011
Naning, Guangxi, China
Zai Lab Site 01022
Heilongjiang, Harbin, China
Zai Lab Site 01008
Shijiazhuang, Hebei, China
Zai Lab Site 01010
Zhengzhou, Henan, China
Zai Lab Site 01034
Wuhan, Hubei, China
Zai Lab Site 01012
Nanjing, Jiangsu, China
Zai Lab Site 01015
Nanchang, Jiangxi, China
Zai Lab Site 01009
Xi'an, Shaanxi, China
Zai Lab Site 01007
Jinan, Shandong, China
Zai Lab Site 01005
Linyi, Shandong, China
Zai Lab Site 01043
Shanghai, Shanghai Municipality, China
Zai Lab SIte 01026
Chengdu, Sichuan, China
Zai Lab Site 01017
Hangzhou, Zhejiang, China
Zai Lab Site 01016
Taizhou, Zhejiang, China
Zai Lab Site 01004
Beijing, China
Zai Lab Site 10018
Fukuoka, Fukuoka, Japan
Zai Lab Site 10017
Fukuoka, Fukuoka, Japan
Zai Lab Site 10019
Kurume, Fukuoka, Japan
Zai Lab Site 10016
Hiroshima, Hiroshima, Japan
Zai Lab Site 10009
Yokohama, Kanagawa, Japan
Zai Lab Site 10015
Kashihara, Nara, Japan
Zai Lab Site 10011
Hirakata, Osaka, Japan
Zai Lab Site 10014
Izumi, Osaka, Japan
Zai Lab Site 10013
Osaka, Osaka, Japan
Zai Lab Site 10012
Sakai, Osaka, Japan
Zai Lab Site 10010
Shizuoka, Sunto-gun, Japan
Zai Lab Site 10003
Shimosuga, Tochigi, Japan
Zai Lab Site 10008
Bunkyō-Ku, Tokyo, Japan
Zai Lab Site 10006
Bunkyō-Ku, Tokyo, Japan
Zai Lab Site 10005
Koto-Ku, Tokyo, Japan
Zai Lab Site 10007
Shinjuku-Ku, Tokyo, Japan
Zai Lab Site 20004
Hilversum, Netherlands
Zai Lab Site 08032
Valencia, Valencia, Spain
Zai Lab Site 14013
Adana, Turkey (Türkiye)
Zai Lab Site 14014
Ankara, Turkey (Türkiye)
Zai Lab Site 14012
Istanbul, Turkey (Türkiye)
Zai Lab Site 14003
Istanbul, Turkey (Türkiye)
Zai Lab Site 21003
London, Greater London, United Kingdom
Zai Lab Site 21011
Chelsea, London, United Kingdom
Zai Lab Site 21012
Sutton, London, United Kingdom
Zai Lab Site 21001
Stoke-on-Trent, Staffordshire, United Kingdom
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.